NCT04101539View on ClinicalTrials.gov

Comparing Pulmonary Vein Isolation to Pulmonary Vein Isolation + OPTIMA Ablation in Patients Undergoing Ablation for Atrial Fibrillation

NACompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

September 1, 2019

Primary Completion Date

September 30, 2025

Study Completion Date

October 1, 2025

Conditions
Atrial Fibrillation Chronic
Interventions
DEVICE

OPTIMA-guided catheter ablation

Patients in the experimental arm will undergo supplemental ablation of OPTIMA-identified sites hypothesized to support/perpetuate chronic atrial fibrillation.

DEVICE

Standard PVI

Standard PVI for AF.

Trial Locations (1)

21287

Johns Hopkins Hospital, Baltimore

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Johns Hopkins University

OTHER

NCT04101539 - Comparing Pulmonary Vein Isolation to Pulmonary Vein Isolation + OPTIMA Ablation in Patients Undergoing Ablation for Atrial Fibrillation | Biotech Hunter | Biotech Hunter